血管加压药治疗脓毒性休克患者的疗效与安全性:系统评价与网状Meta分析
该网状Meta分析检索PubMed、MEDLINE、Embase、Web of Science和Cochrane CENTRAL至2022年5月12日,纳入33项随机对照试验共4966例患者,评估8种血管活性药物治疗脓毒性休克的效果。主要结局为28天全因死亡,次要结局为ICU住院时间,不良事件包括心肌梗死、心律失常、外周缺血及卒中与脑血管事件。累积排序曲线下面积显示去甲肾上腺素联合多巴酚丁胺、肾上腺素、血管加压素、特利加压素、去甲肾上腺素、去甲肾上腺素联合血管加压素、多巴胺、多巴酚丁胺由优到劣排序。多巴胺较去甲肾上腺素、特利加压素和血管加压素ICU住院时间更短;去甲肾上腺素心肌梗死和外周缺血发生率最高,多巴胺心律失常发生率最高,肾上腺素和特利加压素心肌梗死和外周缺血发生率最高。作者认为去甲肾上腺素联合多巴酚丁胺与较低的28天死亡风险相关,多巴胺与较高的28天死亡风险相关。
要点
- 网状Meta分析纳入33项RCT共4966例脓毒性休克患者,比较8种血管活性药物,主要结局为28天全因死亡。
- 累积排序曲线下面积排序从最优到最劣:去甲肾上腺素联合多巴酚丁胺、肾上腺素、血管加压素、特利加压素、去甲肾上腺素、去甲肾上腺素联合血管加压素、多巴胺、多巴酚丁胺。
- 作者认为去甲肾上腺素联合多巴酚丁胺的28天死亡风险低于其他血管活性药物。
- 多巴胺的28天死亡风险高于去甲肾上腺素、特利加压素和血管加压素;多巴胺的ICU住院时间较去甲肾上腺素、特利加压素和血管加压素更短。
- 去甲肾上腺素心肌梗死和外周缺血发生率最高;多巴胺心律失常发生率最高;肾上腺素和特利加压素心肌梗死和外周缺血发生率最高。
适用人群与场景
- 脓毒性休克患者,来自33项随机对照试验共4966例。
研究设计与关键结果
- 研究设计为系统评价与网状Meta分析,检索PubMed、MEDLINE、Embase、Web of Science和Cochrane CENTRAL至2022年5月12日,纳入33项随机对照试验共4966例患者,评估8种血管活性治疗。
- 主要结局28天全因死亡的累积排序曲线下面积排序由优到劣为:去甲肾上腺素联合多巴酚丁胺、肾上腺素、血管加压素、特利加压素、去甲肾上腺素、去甲肾上腺素联合血管加压素、多巴胺、多巴酚丁胺。
- 多巴胺较去甲肾上腺素、特利加压素和血管加压素ICU住院时间显著更短,其他血管活性药物间ICU住院时间无明确差异。
- 不良事件:去甲肾上腺素心肌梗死和外周缺血发生率最高;多巴胺心律失常发生率最高;肾上腺素和特利加压素心肌梗死和外周缺血发生率最高。
证据类型、等级与局限
- 证据类型:系统评价与网状Meta分析,纳入33项随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,去甲肾上腺素联合多巴酚丁胺与脓毒性休克患者较低的28天死亡风险相关。
- 作者认为,多巴胺与较高的28天死亡风险相关,高于去甲肾上腺素、特利加压素和血管加压素。
- 多巴胺与较短的ICU住院时间相关,但心律失常发生率最高;去甲肾上腺素心肌梗死和外周缺血发生率最高;肾上腺素和特利加压素心肌梗死和外周缺血发生率最高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: Septic shock is a distributive shock with decreased systemic vascular resistance and MAP. Septic shock contributes to the most common causes of death in the intensive care unit (ICU). Current guidelines recommend the use of norepinephrine as the first-line vasopressor, whereas adrenergic agonists and vasopressin analogs are also commonly used by physicians. To date, very few studies have synthetically compared the effects of multiple types of vasoactive medications. The aim of this study was to systemically evaluate the efficacy of vasoactive agents both individually and in combination to treat septic shock. Methods: The PubMed, MEDLINE, Embase, Web of Science, and Cochrane Central Register for Controlled Trials (CENTRAL) were searched up to May 12, 2022, to identify relevant randomized controlled trials. A network meta-analysis was performed to evaluate the effect of different types of vasopressors. The primary outcome was 28-day all-cause mortality. The secondary outcome was the ICU length of stay. Adverse events are defined as any undesirable outcomes, including myocardial infarction, cardiac arrhythmia, peripheral ischemia, or stroke and cerebrovascular events. Findings: Thirty-three randomized controlled trials comprising 4,966 patients and assessing 8 types of vasoactive treatments were included in the network meta-analysis. The surface under the cumulative ranking curve provided a ranking of vasoactive medications in terms of 28-day all-cause mortality from most effective to least effective: norepinephrine plus dobutamine, epinephrine, vasopressin, terlipressin, norepinephrine, norepinephrine plus vasopressin, dopamine, and dobutamine. Dopamine was associated with a significantly shorter ICU stay than norepinephrine, terlipressin, and vasopressin, whereas other vasoactive medications showed no definite difference in ICU length of stay. Regarding adverse events, norepinephrine was associated with the highest incidences of myocardial infarction and peripheral ischemia. Dopamine was associated with the highest incidence of cardiac arrhythmia. Epinephrine and terlipressin were associated with the highest incidences of myocardial infarction and peripheral ischemia. Interpretation: The results of this network meta-analysis suggest that norepinephrine plus dobutamine is associated with a lower risk of 28-day mortality in septic shock patients than other vasoactive medications, and the use of dopamine is associated with a higher risk of 28-day mortality due to septic shock than norepinephrine, terlipressin, and vasopressin.
参考来源
- Jia L, Wang P, Li C, et al. THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS. Shock. 2023. PMID: 37548686. doi:10.1097/SHK.0000000000002193
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。